Treating moderately to severely active ulcerative colitis - NICE TA792
MHRA Drug Safety Update, 26 April 2023
1.1 Filgotinib is recommended, within its marketing authorisation, as an option for treating moderately to severely active ulcerative colitis in adults:
when conventional or biological treatment cannot be tolerated, or
if the disease has not responded well enough or has stopped responding to these treatments, and
if the company provides filgotinib according to the commercial arrangement.